NCT00791310

Brief Summary

The objective of this pilot study is to estimate a procedure where the biological samples routinely obtained at the site of suspected infection could be guided by the early realization of a TEP with FDG coupled to scanner X, in patients hospitalized in ICU for severe sepsis of unspecified etiology.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Nov 2008

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2008

Completed
12 days until next milestone

First Submitted

Initial submission to the registry

November 13, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 14, 2008

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2010

Completed
Last Updated

December 31, 2010

Status Verified

December 1, 2010

Enrollment Period

1.9 years

First QC Date

November 13, 2008

Last Update Submit

December 30, 2010

Conditions

Keywords

Medical ICUSevere sepsis

Outcome Measures

Primary Outcomes (1)

  • Percentage of TEP exams useful for the diagnosis and/or with therapeutic implications.

    28 days

Secondary Outcomes (3)

  • Percentage of patients for whom local determinations of TREM and sTREM will have made it possible to identify a strong probability of infection of one or more suspected site

    28 days

  • Reproducibility of the interpretations carried out under the conditions of protocol

    28 days

  • Frequency of the medical and technical complications associated with the procedure

    28 days

Study Arms (1)

TEP

EXPERIMENTAL

Performance of of TEP coupled to scanner X

Drug: Flucis

Interventions

FlucisDRUG

FDG injected i.v

Also known as: FDG
TEP

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient hospitalized with severe sepsis
  • Absence of infected site clearly identified after 48 hours of a conventional diagnosis assessment or suspicion of one or more additional sites
  • Indication of scanner X with injection
  • Informed consent obtained

You may not qualify if:

  • Age over 80
  • Immunocompromised status
  • Surgical intervention within the previous month
  • Hemodynamic instability (defined by the use of more than 0.5µg/kg/min vasopressors)
  • Severe hypoxia (defined by a PaO2/FiO2 ratio lower than 150)
  • Pregnancy
  • Patient already included in another protocol
  • Anaphylaxis to Flucis

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU; Central Hospital

Nancy, 54000, France

RECRUITING

MeSH Terms

Conditions

Sepsis

Condition Hierarchy (Ancestors)

InfectionsSystemic Inflammatory Response SyndromeInflammationPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • sebastien Gibot, MD, PhD

    CHU NANCY

    PRINCIPAL INVESTIGATOR

Central Study Contacts

sebastien GIBOT, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 13, 2008

First Posted

November 14, 2008

Study Start

November 1, 2008

Primary Completion

October 1, 2010

Study Completion

October 1, 2010

Last Updated

December 31, 2010

Record last verified: 2010-12

Locations